Tetrahydrocarbazole amides with potent activity against human papillomaviruses

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 15, 2009, Pages 4110-4114

  Gudmundsson, Kristjan S ^a   Boggs, Sharon D ^a   Sebahar, Paul R ^a   Richardson, Leah D'Aurora ^a   Spaltenstein, Andrew ^a   Golden, Pamela ^a   Sethna, Phiroze B ^a   Brown, Kevin W ^a   Moniri, Kelly ^a   Harvey, Robert ^a   Romines, Karen R ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

Antiviral; Human papillomavirus; Tetrahydrocarbazole

Indexed keywords

1,2,3,4 TETRAHYDROCARBAZOLE DERIVATIVE; N [6 CHLORO 2,3,4,9 TETRAHYDRO 1H CARBAZOL 1 YL] 2 PYRIDINECARBOXAMIDE; TETRAHYDROCARBAZOLE 2 PYRIDINYLAMIDE; TETRAHYDROCARBAZOLE 3 PYRIDINYLAMIDE; TETRAHYDROCARBAZOLE 4 PYRIDINYLAMIDE; TETRAHYDROCARBAZOLE ACETAMIDE; TETRAHYDROCARBAZOLE AMIDE DERIVATIVE; TETRAHYDROCARBAZOLE BENZAMIDE; TETRAHYDROCARBAZOLE CYCLOHEXANECARBOXAMIDE; TETRAHYDROCARBAZOLE PHENYLACETAMIDE; TETRAHYDROCARBAZOLE PHENYLPROPANEAMIDE; TETRAHYDROCARBAZOLE SULFONAMIDE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIVIRAL ACTIVITY; ARTICLE; CIRCULAR DICHROISM; CONTROLLED STUDY; CYTOTOXICITY; DISTRIBUTION VOLUME; DRUG CLEARANCE; DRUG HALF LIFE; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; EXPERIMENTAL DOG; EXPERIMENTAL MONKEY; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; ISOMERISM; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION; VERO CELL; WART VIRUS;

ADMINISTRATION, ORAL; AMIDES; ANIMALS; ANTIVIRAL AGENTS; CARBAZOLES; CERCOPITHECUS AETHIOPS; CYTOCHROME P-450 ENZYME SYSTEM; DOGS; HAPLORHINI; HUMANS; INHIBITORY CONCENTRATION 50; MODELS, CHEMICAL; PAPILLOMAVIRIDAE; RATS; VERO CELLS;

HUMAN PAPILLOMAVIRUS; PAPILLOMAVIRIDAE;

EID: 67649965554     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.06.001     Document Type: Article

References (29)

1. Howley P.M. In: Howley P.M. (Ed). Fundamental Virology (1996), Lippincott-Raven, Philadelphia, PA 947
2. Kroutsky L. Am. J. Med. 102 (1997) 3
3. Wilson F.X. Exp. Opin. Emerg. Drugs 6 (2001) 199
4. Department of Health and Human Services Center for Disease Control and Prevention. CDC factsheet. www.cdc.gov/std/HPV/STDFact-HPV.htm#common.
5. Dunne E.F., Unger E.R., Sternberg M., McQuillan G., Swan D.C., Patel S.S., and Markowitz L.E. J. Am. Med. Assoc. 297 (2007) 813
6. Syrjanen K., Mantyjarvi R., Saarikoski S., Vayrynen M., Syrjanen S., Parkkinen S., Yliskoski M., Saastamoinen J., and Castren O. Br. J. Obstet. Gynaeccol. 95 (1988) 1096
7. Wilson V.G., and Rosas-Acosta G. Curr. Drug Targets-Infectious Disorders 3 (2003) 221
8. Severson J., Evans T.Y., Lee P., Chan T.-S., Arany I., and Tyring S.K. J. Cutan. Med. Surg. 5 (2001) 43
9. Bosch F.X., Lorincz A., Munoz N., Meijer C.J.L.M., and Shah K.V. J. Clin. Pathol. 55 (2002) 244
10. zur Hausen H. Nat. Rev. 2 (2002) 342
11. Schmiedeskamp M.R., and Kockler D.R. Ann. Pharmacother. 40 (2006) 1344
12. Snoeck R. Antiviral Res. 71 (2006) 181
13. Haug C.J. N. Eng. J. Med. 359 (2008) 861
14. For a description of the W12 cell line see:. Stanley M.A., Browne H.M., Appleby M., and Minson A.C. Int. J. Cancer 43 (1989) 672
15. For description of assay see: Boggs, S.; Catalano, J.; Gudmundsson, K.S.; Richardson, L. D.; Sebahar, P. R. WO 2005/023245.
16. Harvey R., Brown K., Zhang Q., Gartland M., Walton L., Talarico C., Lawrence W., Selleseth D., Coffield N., Leary J., Moniri K., Singer S., Strum J., Gudmundsson K., Biron K., Romines K.R., and Sethna P. Antiviral Res. 82 (2009) 1
17. Gudmundsson, K. S.; Sebahar, P. R.; Richardson, L.; Catalano, J. G.; Boggs, S. D.; Spaltenstein, A.; Sethna, P. B.; Brown, K. W.; Harvey, R.; Romines, K. R. Bioorg. Med. Chem. Lett. 2009, doi: 10.1016/j.bmcl.2009.05.003.
18. Refsgaard H.H.F., Jensen B.F., Christensen I.T., Hagen N., and Brockhoff P.B. Drug Dev. Res. 67 (2006) 417
19. Gleeson M.P. J. Med. Chem. 51 (2008) 817
20. Tautomer of 2-formylcyclohexanone prepared as described by:. Tishler M., Gal G., and Stein G.A. Org. Synth. 39 (1959) 27
21. Borsche W., Witte A., and Bothe W. Justus Liebigs Ann. Chem. 359 (1908) 49
22. Borsche W., and Kienitz G.A. Chem. Ber. 43 (1910) 2335
23. 50 values to be virtually identical in keratinocytes and fibroblasts. HFF cells (fibroblasts) were amenable to high throughput screening, whereas keratinocytes are not.
24. 2; flow rate 2 mL/min at 2250 psi, 50 °C on Diacel AD-H column (Chiral Technologies), 4.6 × 250 mm, 5 μm; R-isomer retention time 12.37 min; S-isomer retention time 16.11 min.
25. -1. The Gaussian 98 Suite of computational programs was used to calculate model VCD spectra. Stereochemical assignments made by comparing calculated and measured spectra. For reference:. Chesseman J.R., Frisch M.J., Devlin F.J., and Stephens P. J. Chem. Phys. Lett. 252 (1996) 211
26. Stephens P.J., and Devlin F.J. Chirality 12 (2000) 172 Assignments were later confirmed by X-ray crystallography of 41
27. 2; flow rate 2 mL/min at 1500 psi, 40 °C on Diacel AS-H column (Chiral Technologies), 4.6 × 250 mm, 5 μm; For 41 retention time 5.08 min, for 42 retention time 7.45 min.
28. Chirality confirmed by X-ray crystallography of 41.
29. Boggs S.D., Cobb J.D., Gudmundsson K.S., Jones L.A., Matsuoka R.T., Millar A., Patterson D.E., Samano V., Trone M.D., Xie S., and Zhou X. Org. Process Res. Dev. 11 (2007) 539